Intrinsiqq
Impact Biomedical Inc. logo

Impact Biomedical Inc.

IBO

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$442M
EPS$0.88
P/E4.66
P/FCF-870.21
EV/EBITDA-86.51
FCF Yield–
Div. Yield–
Net Debt/FCF0.0x
Impact Biomedical Inc. intrinsic value
52-Week Range
$2.68$6.63

Profitability & Returns

Revenue (FY)

$32K

Net Income (TTM)

$789K

▲ +52.1% YoY

Op. Margin

-13381.25%

ROIC

-27.98%

▲ +46.4pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$508K

▲ +33.8% YoY

Op. Cash Flow (TTM)

-$508K

▲ +33.8% YoY

Net Debt

-$10K

Net Cash Position

Cash & Equiv.

$10K

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with IBO

CompareIntrinsic value
LYELLyell Immunopharma, Inc.
$14.86-0.93%10
GRDXGridAI Technologies Corp.
$4.92+5.35%0
NTHINeonC Technologies Holdings
$3.49+9.06%10
BDPTBioadaptives Inc.
$0.00-13.67%25
ALTAltimmune, Inc.
$2.08+5.58%10
JUNSJupiter Neurosciences Inc.
$2.20+3.29%10
SKVISkinvisible Inc.
$0.18+15.24%0
ADTXAditxt Inc.
$0.00+40.00%20

Impact Biomedical (IBO) in four numbers

Fair value (revenue)
$0.00
Price $4.10 is 562233% above it.
Intrinsic Value
Quality score
20/100
Best check: net debt, -$10000. Weakest: return on capital, -28.0%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
4.66
Price to free cash flow -870.21.
Financials

Questions about Impact Biomedical

Is Impact Biomedical (IBO) overvalued?

At $4.10, Impact Biomedical's price is 562233% above the $0.00 a share fair value that Intrinsiqq's calculator gets from its revenue. It trades at 4.66 times earnings. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Impact Biomedical's fair value?

Intrinsiqq's calculator puts Impact Biomedical's fair value at $0.00 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 3.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.00. Every input can be changed on the Intrinsic Value tab.

Is Impact Biomedical a high-quality business?

Impact Biomedical scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is net debt at -$10000, and its weakest is return on capital at -28.0%. The Quality tab shows every check against its target.

Does Impact Biomedical (IBO) pay a dividend?

No. Impact Biomedical (IBO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 4 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in IBO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing IBO

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.